• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks
    medical device investing

    Covalon to Expand US Footprint with AquaGuard Deal

    Gabrielle Lakusta
    Sep. 21, 2018 10:30AM PST
    Medical Device Investing
    OTCQX:CVALF

    Covalon Technologies announced on Thursday that it will acquire US-based AquaGuard, allowing its product reach in the country to expand.

    Covalon Technologies (TSXV:COV,OTCQX:CVALF) announced on Thursday (September 20) it will acquire US-based AquaGuard allowing for its product reach in the country to expand.

    This acquisition will allow Covalon’s products to be sold throughout the US by AquaGuard’s specialized salesforce, a division of Cenorin.

    Under the agreement terms, Covalon will pay over US$12.3 million (C$16.1 million) to AcquaGuard’s business from Cenorin. The company expects the deal to close within 60 days, subject to all regulatory approvals. All of the directors from Covalon’s board have approved this agreement.

    “AquaGuard’s experienced sales team and specialized product line are a perfect synergistic fit for Covalon’s business,” Covalon’s CEO, Brian Pedlar said in the press release. Covalon’s customer base includes over 1,500 hospitals and clinics in the US, but AquaGuard may expand this further in the country.

    Pedlar explained AquaGuard’s sales team has already built relationships with hospitals and clinicians — which should result in a smooth transition moving the product line to Covalon. AquaGuard’s president, Gerry Arambula, said the company plans to sell Covalon’s products through third-party distribution partners, including Amazon (NASDAQ:AMZN) in addition to the current customer base.

    On the other hand, Covalon will sell the products from the newly acquired company through its own international distribution channels.

    AquaGuard has a line of specialty wound-covering products. The products’ moisture protection can cover a wound as well as surgical and vascular spots on the body while the patient is showering.

    Covalon also has a line of wound care products. Its ColActive brand of Bio-Matrix dressings have helped head chronic wounds and prevented limb amputation in some cases. The company is looking to expand to markets with larger diabetic populations as many dressings are suitable for this market.

    The existing AquaGuard leadership team will remain in prominent roles in the company going forward.

    Patients can use AquaGuard’s products without the help of medical professionals, the variety of products have a use for all over the body. Aside from this division, Cenorin has two other divisions: HLD Systems and ThermaSure.

    Covalon is based in Canada and, along with its wound care products, the company has products for infection prevention and multi-stage surgery care.

    Investor takeaway

    On the TSXV, Covalon’s share price increased 5.29 percent over Thursday’s trading period to close at C$9.16. As for the OTCQX, the company’s share price had a 4.72 percent increase to reach US$7.01 as of market close.

    Investors looking for more information on this acquisition should expect to hear about it closing within the next few months. In terms of additional news, investors can follow both companies’ respective sites for updates on products and commercial updates.

    Don’t forget to follow @INN_LifeScience for real-time updates!

    Securities Disclosure: I, Gabrielle Lakusta, hold no direct investment interest in any company mentioned in this article.

    otcqx:cvalfcovalon technologiestsxv:covmedical device investing
    The Conversation (0)

    Go Deeper

    AI Powered
    Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

    Top 5 Small-cap Pharma Stocks of 2025

    TSXV:SBM

    Sirona Biochem Secures Strategic Investment Agreements and New Joint Venture with Promura GmbH

    Latest News

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Medical Device Investing Stocks

    Cardiex Limited

    CDX:AU

    Cleo Diagnostics

    COV:AU

    Ocumetics Technology

    OTC:CA

    Premier Health of America

    PHA:CA

    Bloom Health Partners

    BLMH:CNX

    Applied UV

    AUVI:NSD
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES